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Tajima et al., page 569
Patients with Fabry disease suffer from a wide range of
symptoms, including pain, skin manifestations, renal
problems, and cardiac disorders. The X-linked disease is
caused by the lysosomal accumulation of globotriaosylcer-
amide (Gb3) due to mutations in GLA, the gene encoding
a-galactosidase A. Current treatment involves enzyme
replacement therapy, wherein recombinant enzyme is
introduced via infusion in an effort to break down the
Gb3. The therapy has had its successes, but there is room
for improvement. The therapy relies on mannose 6-phos-
phate (M6P) receptors to bind the recombinant enzyme
and bring it into the cells. Because the recombinant
enzymes do not contain a high level of M6P, this can be
limiting, and some cells can not incorporate enough of
the enzyme to signiﬁcantly reduce the amount of Gb3
accumulation. Additionally, patients can have allergic
reactions to the foreign proteins and develop antibodies
that reduce the efﬁcacy of the treatment. To alleviate these
problems, Tajima et al. tweak a few amino acids in the
active site of the endogenous enzyme a-N-acetylgalactosa-
mindase (NAGA) to create a modiﬁed version that will
recognize and break down Gb3. The thought is that the
modiﬁed NAGA contains more M6P and so will be better
incorporated into cells, and that the enzyme also should
not cause an immune response because it is similar enough
to the natural form of NAGA. The authors demonstrate
that, in mice, the modiﬁed NAGA is indeed well incorpo-
rated into a number of affected tissues. They also ﬁnd
that human patient serum shows no immunoreactivity
to the modiﬁed enzyme. It is hoped that these results
will translate into an improved and effective treatment
for patients with Fabry disease.
Privacy in Biobanks
Kaufman et al., page 643
Involving the general public in genetic research is now
more important than ever. Not only are new ﬁndings
increasing the amount of useful information that can actu-
ally affect people’s lives, but new study designs necessitate
the participation of a large number of individuals. With
this high level of public involvement has come the respon-
sibility of ensuring that participants are well informedabout the consequences of their contributions and that
the privacy of each individual is maintained. Large bio-
banks have been created for the storage of participant
samples and information, and many safeguards have
been implemented for ensuring the safety of these data,
but new reports have suggested that anonymous samples
may not be as unidentiﬁable as originally thought.
Discrimination by insurers and employers is not the only
possible negative outcome; violating the right of individ-
uals to share their personal medical information in
a manner that suits them is also harmful. In addition,
the public’s perception that privacy might be breeched
in these biobanks may hinder participation even if no
such possibility does actually exist. Kaufman et al.
report the results of a national survey that assesses how
privacy concerns, study design, potential beneﬁts, type of
researcher, and data sharing affect the willingness of indi-
viduals to participate in a large cohort study. The authors
conclude that, although many respondents do express
concern about privacy, the majority say that they would
share their data with researchers, particularly if they are
conﬁdent that they will maintain control over the use of
their information and if they beneﬁt from the study.
GWAS of Lung Cancer by Histology
Landi et al., page 679
Carcinoma refers to the uncontrolled proliferation and
migration of epithelial cells. Such malignant cancers can
arise from different tissue sources, including glandular
and squamous tissue. Malignant cancers arising from glan-
dular tissue are referred to as adenocarcinomas, and those
arising from squamous tissue are called squamous cell carci-
nomas. Lung cancer is most often a carcinoma and can be
histologically classiﬁed as being either small cell lung
cancer or non-small cell lung cancer. Treatment of lung
cancer differs between these two types of carcinomas.
Both adenocarcinomas and squamous cell carcinomas are
non-small cell cancers and often respond to chemotherapy
and radiation. Although long-term exposure to tobacco
smoke is thought to be the primary cause of lung cancer,
a genetic component does exist. Remarkably, there is little
that is known about the genetics of the different histolog-
ical subtypes of lung cancer. In this issue, Landi et al. set
out to discover genetic variants contributing to lung cancer
histology. Through performing a genome-wide association1Science Editor, AJHG; 2Deputy Editor, AJHG
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study of adenocarcinomas, squamous cell carnicomas, and
small cell carcinomas, this group validates previous ﬁnd-
ings reporting association of 5p15, 15q25, and 6p21 with
lung cancer. In addition, they identify a SNP in TERT that
is signiﬁcantly associated with adenocarcinoma in both
smokers and nonsmokers. This study contributes to the
task of ferreting out the interplay between smoking and
genetics in the development of lung cancer.
Imputation Error and Power
Huang et al., page 692
SNP analyses of entire genomes are now commonplace in
genetic studies. As the ﬁeld evolves, the tools available for
these analyses progress and change. One quickly evolving
instrument is the platform used for genotyping; the SNP
arrays are growing to include a larger and larger number
of SNPs. Although many SNPs overlap between arrays,
not all genotyping platforms contain exactly the same
set of SNPs. Because of the growing number of genotyping
platforms available, geneticists are using and sharing data
and genotype information obtained from a variety of
SNP arrays. In an effort to increase efﬁciency and decrease
cost, scientists and statisticians have developed a means to
substitute one SNP for another when data is missing from
one genotyping platform or another. This process of substi-
tution is called imputation. Use of imputation in genome-
wide association studies (GWAS) is often limited by
increased error rates and loss of power for the detection
of association. Genotyping a larger number of people
than necessary for nonimputed data can help to overcome
these obstacles. Here, Huang et al. examine the degree of
population inﬂation required for maintaining power in
imputation GWAS. They ﬁnd that even small errors in
imputation require a large number of additional subjects
to be genotyped in order to maintain power for the detec-540 The American Journal of Human Genetics 85, 539–540, Novemtion of associations. This number, however, is dependent
on the population used. For example, fewer additional
samples are needed when imputing European samples
than when imputing African populations, who have
more diverse genomes. This manuscript provides a guide
for study design when imputing genotypes.
TRPM1 and Congenital Stationary Night Blindness
Audo et al., page 720; Li et al., page 711;
van Genderen et al., page 730
Mutations in NYX and GRM6 have been identiﬁed in
patients with complete congenital stationary night blind-
ness (cCSNB), but there remain cases in which the etiology
remains unknown. Now, recent work in a horse model has
shed some light on the topic. The Appaloosa horse suffers
from a phenotype of night blindness that is very similar to
cCSNB in humans, and expression studies in the horse
have demonstrated that the gene TRPM1, which encodes
a transient receptor potential channel, is downregulated
in the retina. In addition, the proteins encoded by NYX
and GRM6 have been shown to modulate the TRPM1
channel. These ﬁndings have spurred three independent
groups to screen for mutations in TRPM1 in their patients
with cCSNB. The groups, led by Li, Audo, and van Gen-
deren, identify different TRPM1 mutations in a large
proportion of their patients. van Genderen et al. also
further characterize the electroretinograms (ERGs) of their
patients and compare them to those of patients withmuta-
tions in the other cCSNB genes. The authors report that the
ERGs of patients with mutations in TRPM1 are identical to
those of patients with dysfunctional NYX and that they
differ from those of patients with GRM6 mutations. These
collective data offer insight into the pathways involved in
night vision and illuminate the genetic etiology of cCSNB
in a signiﬁcant percentage of patients.ber 13, 2009
